Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type XII alpha 1 chain (COL12A1)
- Target
- COL12A1
- Molecular classification
- Collagen, Fibril-associated collagen with interrupted triple helices (FACIT), Extracellular matrix protein, Structural protein, Proteoglycan (sometimes classified as such due to domain structure)
01
Overview
Collagen type XII alpha 1 chain is an extracellular matrix protein of the FACIT collagen family. It forms homotrimers and associates with type I collagen fibrils, modifying their interactions with the surrounding matrix. COL12A1 is essential for tissue integrity, tendon differentiation, and biomechanical strength; its absence is associated with disrupted cell polarity, poor matrix deposition, and tissue weakness. Mutations cause Bethlem myopathy 2 and Ullrich congenital muscular dystrophy 2. Dysregulation or high expression is associated with cancer progression, tissue remodeling, and increased metastatic potential. COL12A1 is not a typical therapeutic target but its expression status may be useful as a biomarker in oncological and connective tissue conditions
- Other names
- Collagen alpha-1(XII) chainCOL12A1Lcollagen type XII proteoglycanBA209D8.1BTHLM2DJ234P15.1EDSMYPUCMD2collagen, type XII, alpha 1
02
Mechanism of action
Not applicable (direct pharmacological targeting mechanisms are not described for COL12A1)
03
Biological functions
Extracellular matrix organizationMaintenance of tissue integrityCoordination of collagen fibril assemblyCell-matrix communicationRegulation of biomechanical strength of tissuesModulation of cell polarity and adhesionTissue remodeling during growth and differentiation
04
Disease associations
Musculoskeletal diseases (Bethlem myopathy 2, Ullrich congenital muscular dystrophy 2)Cancer (prognostic biomarker in gastric, colorectal, and ovarian cancers)Connective tissue disordersAnterior cruciate ligament rupture predisposition (in select populations)Diabetic nephropathy (profibrotic signaling)
05
Safety considerations
Mutations lead to congenital muscular dystrophy and myopathies, posing therapeutic challenges in connective tissue repair or regenerationAberrant expression linked to tissue fragility and tumor progression
06
Interacting drugs
No direct therapeutic drugs known to target COL12A1; expression may be modulated indirectly by drugs affecting connective tissue remodeling
07
Biomarkers
COL12A1 expression (potential biomarker for aggressive disease phenotypes in some cancers such as gastric and colorectal carcinoma)
Beyond the preview
Go deeper on Collagen type XII alpha 1 chain (COL12A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Collagen type XII alpha 1 chain (COL12A1).